X

Drug Profile

SKL 15508

Alternative Names: SKL 20540; SKL A4R; SKL15508

Latest Information Update: 22 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SK biopharmaceuticals
Class Nootropics; Small molecules
Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Schizophrenia
No development reported Cognition disorders; Mental disorders

Most Recent Events

22 Feb 2022 SKL 15508 is still in phase I trials for Schizophrenia in USA (SK biopharmaceuticals pipeline, February 2022)
28 Dec 2021 No recent reports of development identified for phase-I development in Mental-disorders(In volunteers) in South Korea (PO)
29 Sep 2021 No development reported - Phase-I/II for Cognition disorders in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com